Fig. 1 a
From: Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
Proportion of patients with comorbidities – by overall population, migraine type and monotherapy and add-on therapy. b Proportion of patients with previous or current preventive treatment – Overall population and by migraine type. *Botulinum toxin type A, antiepileptics, antimigraine preparations, flunarizine dihydrochloride, galcanezumab, local anaesthetics. **Magnesium oxide, botulinum toxin type A, antiepileptics, antimigraine preparations, local anaesthetics, magnesium, venlafaxine. Percentages are based on the total number of subjects in the full analysis set